Enlightenment of the latest pharmacological research: the efficacy of minor cannabinoids is no less than CBD

DATE:2020-12-25 18:02

Pharmacological activity of cannabinoid

A study by a laboratory at the University of Saskatchewan in Canada tried to find out. The researchers found that THCA, thcv, CBDA, cbdv, CBG and CBC all play positive roles in animal experiments.

CBD Packaging

Modern science has shown that endogenous agonists 2-arachidonylglycerol (2-AG), arachidonic amide (AEA) and related anabolic and catabolic enzymes constitute the endogenous cannabinoid system (ECS), which exists in both vertebrates and invertebrates.
CB1 and CB2 are the two most studied cannabinoid receptors. Activation of CB1 receptor can inhibit stress perception, activate reward pathway, and regulate emotion, memory and cognition as well as central hormone homeostasis.
THC functions in part by activating CB1 and CB2. Therefore, thc is a partial agonist of CB1 and CB2, but the pharmacology of CBD remains unclear.
CBD has been described as a negative allosteric regulator of CB1, an antagonist of CB2, an agonist of gpr18 and an antagonist of GPR55.
Potential interactions of cannabinoid mixtures
This study provides important implications for the therapeutic potential and practicability of plant cannabinoids.
The eight cannabinoids (THC, CBD and six minor cannabinoids) tested had a certain level of binding with CB1. But in addition to THC, CBD, including other cannabinoids, has weak binding with CB1. Most cannabinoids can also bind to CB2, and the binding of CBD to CB2 receptor is weak.
Studies have shown that THCA may have neuroprotective and anti-inflammatory effects mediated by CB1, CB2 and PPAR γ at sufficiently high concentrations and in the absence of other cannabinoids.
In mice, THC, THCA and thcv were found to relieve pain, but CBD was not obvious. THC, CBD, THCA, thcv and CBG all had positive effects on reducing anxiety.
The authors conclude that THCA and thcv combined with CB1 and CB2 can reduce pain, inflammation and anxiety when used without other cannabinoids. This conclusion clarifies that the clinical application value of monocannabinoid preparation is more and more prominent.

CONTACT US

Email: *
Mobile:
Message: *

Copyright @ 2010-2017, Safecare NETWORK TECHNOLOGY CO.,LIMITED https://hfsafecaremed.en.alibaba.com/ www.marijuana420packaing.com

Powered By Ke Wei

CONTACT US

Email: *
Mobile:
Message: *